Skip to main content
. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895

Fig. 3.

Fig. 3

Kaplan Meier survival curves estimating the cumulative proportion that experienced the primary endpoint at day 30, considering patients with baseline PaO2/FiO2 ≥ 200 mmHg (3a) and patients with baseline PaO2/FiO2<200 mmHg (3b). Cox regression model stratified by clinical center fitted to estimate the hazard ratio (HR) of primary endpoint in arm A vs arm B; 95% confidence intervals (CI) are reported. Primary endpoint: time to clinical improvement of 2 points on a 7-point category ordinal scale. Arm A: Sarilumab plus standard of care. Arm B: standard of care.